Skip to content

Everett E. Vokes

The University of Texas MD Anderson Cancer Center

3 papers in the Anchorcite directory, published between 2015 and 2016, cited 23,218 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Luis G Paz-Ares · 2 papers
  • David Robert Spigel · 2 papers
  • Martin B. Steins · 2 papers
  • Neal Ready · 2 papers
  • Esther Holgado · 2 papers
  • Jérôme Fayette · 2 papers
  • Elena V Poddubskaya · 2 papers
  • George R. Blumenschein · 2 papers

Papers

  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations

    BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…

  2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 8,551 citations

    BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4…

  3. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine · 2016 · 5,194 citations

    BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.…

Metadata from OpenAlex (CC0).